SCHEMBL589285

SCHEMBL589285

CC1(C)OC[C@@H](C[O])O1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL589481 1.00
SCHEMBL4421192 1.00
SCHEMBL714053 0.82 CA2 (0.49)
SCHEMBL85627 0.81
SCHEMBL7118718 0.81
SCHEMBL898528 0.81
SCHEMBL7154999 0.80 CA2 (0.50)
SCHEMBL740693 0.80
SCHEMBL6125258 0.80
SCHEMBL4135508 0.80

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-100409840-C Methods for increasing bone formation using inhibitors of glycogen synthase kinase-3 betta HOFFMANN LA ROCHE (CH) 2008-08-13 CN claimed
CN-117143145-A Preparation method of dioleoyl phosphatidylethanolamine 安徽昊帆生物有限公司 2023-12-01 CN disclosed
CN-113999259-A Preparation method of (R) -glycerolphosphinyl-N-Boc ethanolamine sodium salt 苏州昊帆生物股份有限公司 2022-02-01 CN disclosed
EP-2801574-B1 ACID ADDUCT SALTS OF SUBSTITUTED PYRIDINE COMPOUND AS CHOLESTERYL ESTER TRANSFER PROTEIN (CETP) INHIBITORS DAIICHI SANKYO CO LTD (JP) 2016-07-27 EP disclosed
US-9321747-B2 Acid addition salt of substituted pyridine compound DAIICHI SANKYO COMPANY, LIMITED (JP) 2016-04-26 US disclosed
US-20150299169-A1 ACID ADDITION SALT OF SUBSTITUTED PYRIDINE COMPOUND DAIICHI SANKYO COMPANY, LIMITED (JP) 2015-10-22 US disclosed
CN-102137847-B Bicyclic heterocycles as MEK kinase inhibitors GENENTECH INC 2015-06-10 CN disclosed
EP-2801574-A1 ACID ADDUCT SALT OF SUBSTITUTED PYRIDINE COMPOUND DAIICHI SANKYO COMPANY, LIMITED (JP) 2014-11-12 EP disclosed
US-8114989-B2 Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors ASTRAZENECA AB (SE) 2012-02-14 US disclosed
US-20100210648-A1 PYRAZOLYLAMINOPYRIMIDINE DERIVATIVES USEFUL AS TYROSINE KINASE INHIBITORS ASTRAZENECA R&D (SE) 2010-08-19 US disclosed
US-7476676-B2 Methods for increasing bone formation using inhibitors of glycogen synthase kinase-3β ROCHE PALO ALTO LLC (US) 2009-01-13 US disclosed
EP-1465610-B1 USE OF A GSK-3BETA INHIBITOR IN THE MANUFACTURE OF A MEDICAMENT FOR INCREASING BONE FORMATION HOFFMANN LA ROCHE (CH) 2008-12-31 EP disclosed
US-20080287437-A1 Pyrazolylaminopyrimidine Derivatives Useful as Tyrosine Kinase Inhibitors ASTRAZENECA AB (SE) 2008-11-20 US disclosed
CN-100409840-C Methods for increasing bone formation using inhibitors of glycogen synthase kinase-3 betta HOFFMANN LA ROCHE (CH) 2008-08-13 CN disclosed
EP-1899323-A2 PYRAZOLYLAMINOPYRIMIDINE DERIVATIVES USEFUL AS TYROSINE KINASE INHIBITORS AstraZeneca AB (SE) 2008-03-19 EP disclosed
WO-2006123113-A2 PYRAZOLYLAMINOPYRIMIDINE DERIVATIVES USEFUL AS TYROSINE KINASE INHIBITORS ASTRAZENECA AB (SE) 2006-11-23 WO disclosed
CN-1703207-A Methods for increasing bone formation using inhibitors of glycogen synthase kinase-3 betta HOFFMANN LA ROCHE (CH) 2005-11-30 CN disclosed
CN-1185229-C 3-indolyl-4-phenyl-1H-pyrrole-2, 5-dione derivatives as glycogen synthase kinase-3 beta inhibitors HOFFMANN LA ROCHE (CH) 2005-01-19 CN disclosed
EP-1307447-B1 3-INDOLYL-4-PHENYL-1H-PYRROLE-2,5-DIONE DERIVATIVES AS INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3BETA HOFFMANN LA ROCHE (CH) 2004-12-15 EP disclosed
US-6479490-B2 TREATMENT OF DISEASES CHARACTERIZED BY EXCESS TH2 CYTOKINES AND/ OR AN EXCESS IGE PRODUCTION. SYNTEX (U.S.A.) LLC 2002-11-12 US disclosed